Multicenter SPAN Trial of Fasudil in Ischemic Stroke
Stroke · 2025
DOI: 10.1161/strokeaha.125.050977 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stroke, 2025. Verfasst von Takahiko Imai und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA (T.I., A.L.d.M., X.J., T.Q., J.B.M., C.A.). Hauptthemen laut MEDLINE: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine, Brain Ischemia, Ischemic Stroke, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NHLBI NIH HHS.
Themen: Schlaganfall
Abstract (Originalsprache)
BACKGROUND: The SPAN (Stroke Preclinical Assessment Network) is a confirmatory multicenter trial network to test cerebroprotective interventions in experimental acute stroke. In a first-of-its-kind trial, SPAN tested 6 interventions in a rodent model of transient focal ischemic stroke. Here, we report the efficacy of fasudil, an isoform-nonselective rho-associated kinase inhibitor, on primary and secondary outcomes in the SPAN trial. METHODS: Fasudil was administered at 10 mg/kg intraperitoneally every 12 hours for 6 doses starting 5 minutes before reperfusion in a 60-minute endovascular filament middle cerebral artery occlusion model. The active treatment arm (n=345) was compared with the pooled intraperitoneal and intravenous vehicle arms (n=344). In addition to healthy young mice, the trial included aging mice (16±1 months), diet-induced obese mice, and spontaneously hypertensive rats. The a priori fasudil substudy design stipulated the modified corner test performance on day 28 as the primary end point and separate analyses for mice and spontaneously hypertensive rats using the modified intention-to-treat cohort. RESULTS: Fasudil improved the primary outcome end point in mice (probabilistic index point estimate, 0.57; P =0.022). The effect appeared stronger in aging mice and when ischemia was induced during the active circadian stage. Fasudil did not show any benefit in the spontaneously hypertensive rats. Alternative analyses using the per-protocol population and imputation generally yielded similar conclusions. CONCLUSIONS: Our results reveal a favorable therapeutic profile for fasudil, supporting future translational development of rho-associated kinase inhibitors in ischemic stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, MA (T.I., A.L.d.M., X.J., T.Q., J.B.M., C.A.).
- Department of Neurology, Zilkha Neurogenetic Institute, Keck School of Medicine of USC, Los Angeles, CA (J.L., K.A.N., P.D.L.).
- Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY (M.-H.C., M.A.D.).
- Department of Neurology, Yale University School of Medicine, New Haven, CT (L.S.B.B., L.H.S.).
- Division of Hematology/Oncology, Department of Internal Medicine (R.B.P., M.K., A.K.C.), University of Iowa.
- Department of Neurology, McGovern Medical School, University of Texas Health Science Center, Houston (A.C., J.A., L.D.M.C.).
ORCID-Profile: Takahiko Imai, Andreia Lopes de Morais, Xuyan Jin, Jessica Lamb, Karisma A Nagarkatti, Mu-Hsun Chen, Ligia S B Boisserand, Rakesh B Patel, Mariia Kumskova, Anjali Chauhan, Krishnan M Dhandapani, Mohammad B Khan, Pradip K Kamat, Yanrong Shi, Suyi Cao, Basavaraju G Sanganahalli, Joseph B Mandeville, Patrick D Lyden, David C Hess, Enrique C Leira, Anil K Chauhan, Jaroslaw Aronowski, Louise D McCullough, Raymond C Koehler, Lauren H Sansing, Márcio A Diniz, Cenk Ayata
Förderung
- NINDS NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Imai, T., Morais, A. L., Jin, X., Qin, T., Lamb, J., Nagarkatti, K. A., Chen, M. H., Boisserand, L. S. B., Patel, R. B., Kumskova, M., Chauhan, A., Dhandapani, K. M., Khan, M. B., Kamat, P. K., Shi, Y., Cao, S., Sanganahalli, B. G., Mandeville, J. B., Lyden, P. D., …, & SPAN Investigators (2025). Multicenter SPAN Trial of Fasudil in Ischemic Stroke. Stroke. https://doi.org/10.1161/strokeaha.125.050977
Vancouver
Imai T, Morais AL, Jin X, Qin T, Lamb J, Nagarkatti KA, et al. Multicenter SPAN Trial of Fasudil in Ischemic Stroke. Stroke. 2025. doi:10.1161/strokeaha.125.050977
BibTeX
@article{Imai2025,
author = {Imai, Takahiko and Morais, Andreia Lopes de and Jin, Xuyan and Qin, Tao and Lamb, Jessica and Nagarkatti, Karisma A and Chen, Mu-Hsun and Boisserand, Ligia S B and Patel, Rakesh B and Kumskova, Mariia and Chauhan, Anjali and Dhandapani, Krishnan M and Khan, Mohammad B and Kamat, Pradip K and Shi, Yanrong and Cao, Suyi and Sanganahalli, Basavaraju G and Mandeville, Joseph B and Lyden, Patrick D and Hess, David C and Leira, Enrique C and Chauhan, Anil K and Aronowski, Jaroslaw and McCullough, Louise D and Koehler, Raymond C and Sansing, Lauren H and Diniz, Márcio A and Ayata, Cenk and SPAN Investigators, SPAN Investigators},
title = {Multicenter SPAN Trial of Fasudil in Ischemic Stroke},
journal = {Stroke},
year = {2025},
doi = {10.1161/strokeaha.125.050977}
}
EUVIMED